| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Insulin, Fasting
MessagePerforming Lab: Central Lab
Test Code
4625
Alias/See Also
Sunquest: INSU; Insulin Level, Insulin Ultrasensitive
CPT Codes
83525
Preferred Specimen
0.3 mL Serum Separator (gold-top) tube
Minimum Volume
0.2 mL
Other Acceptable Specimens
Red, Red/Gray
Instructions
Collection:
Patient must be fasting = 8 hours.
Processing:
Aliquot and freeze at -20º C within 24 hours of collection.
Patient must be fasting = 8 hours.
Processing:
Aliquot and freeze at -20º C within 24 hours of collection.
Transport Temperature
Refrigerated
Specimen Stability
Refrigerated: 24 hours
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Plasma is not an acceptable specimen type. Hemolyzed samples, Specimen not frozen within 24 hours of collection.
Methodology
Chemiluminesence
Setup Schedule
Monday - Friday
Report Available
Same day
Limitations
This assay has no cross-reactivity with proinsulin
Patients on insulin therapy are prone to development of anti-insulin antibodies. These antibodies may interfere with the assay.
For assays employing antibodies, the possibility exists for interference by heterophile antibodies in the patient sample. Patients who have been regularly exposed to animals or have received immunotherapy or diagnostic procedures utilizing immunoglobulins or immunoglobulin fragments may produce antibodies, e.g. HAMA, that interfere with immunoassays. Additionally, other heterophile antibodies such as human anti-goat antibodies may be present in patient samples. Such interfering antibodies may cause erroneous results. Therefore, carefully evaluate the results of patients suspected of having these antibodies.
As a general rule, results from these types of assays should be interpreted in light of the total clinical presentation of the patient, including: symptoms, clinical history, and data from additional tests.
Patients on insulin therapy are prone to development of anti-insulin antibodies. These antibodies may interfere with the assay.
For assays employing antibodies, the possibility exists for interference by heterophile antibodies in the patient sample. Patients who have been regularly exposed to animals or have received immunotherapy or diagnostic procedures utilizing immunoglobulins or immunoglobulin fragments may produce antibodies, e.g. HAMA, that interfere with immunoassays. Additionally, other heterophile antibodies such as human anti-goat antibodies may be present in patient samples. Such interfering antibodies may cause erroneous results. Therefore, carefully evaluate the results of patients suspected of having these antibodies.
As a general rule, results from these types of assays should be interpreted in light of the total clinical presentation of the patient, including: symptoms, clinical history, and data from additional tests.
Reference Range
1.9-23.0 uIU/mL
Clinical Significance
Insulin is a hormone secreted by the pancreas which regulates the uptake and utilization of glucose and is also involved in the regulation of protein synthesis and triglyceride storage.
One of insulin’s primary clinical uses is in the diagnosis and management of diabetes mellitus. Some other uses of insulin measurements include: follow-up and stabilization of insulin-treated diabetics and in predicting complications of Type II diabetes (NIDDM).
One of insulin’s primary clinical uses is in the diagnosis and management of diabetes mellitus. Some other uses of insulin measurements include: follow-up and stabilization of insulin-treated diabetics and in predicting complications of Type II diabetes (NIDDM).
